Calcium Citrate Malate represents a pharmaceutically optimised salt form in which counter-ion selection modifies the physicochemical properties of the parent molecule without altering its core pharmacophore or intrinsic pharmacodynamic activity. The crystal lattice energy of Calcium Citrate Malate determines its thermodynamic stability, dissolution behaviour, and susceptibility to polymorphic transformation under manufacturing process conditions. PDE assessment for Calcium Citrate Malate in shared manufacturing facilities is based on the pharmacological activity of the parent active moiety, with the MACO calculation adjusted using the molecular weight ratio of free base or acid to salt form.
The OEB assigned to Calcium Citrate Malate in pharmaceutical manufacturing is determined by structured potency banding based on its pharmacological target, NOAEL from repeat-dose studies, genotoxic classification under ICH M7, and reproductive toxicant status.
